When she got home, she threw up and collapsed into bed, falling asleep around 5 p.m. The following morning, she went to urgent care, where doctors took an X-ray of her chest. It was the same day they ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...